The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity

This study has been completed.

Sponsor:

Information provided by:

Far Eastern Memorial Hospital

ClinicalTrials.gov Identifier:

NCT00632892

First received: March 3, 2008

Last updated: March 10, 2008

Last verified: February 2008

History of Changes

Tracking Information
First Received Date ^ICMJE	March 3, 2008
Last Updated Date	March 10, 2008
Start Date ^ICMJE	December 2007
Primary Completion Date	January 2008 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00632892 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity
Official Title ^ICMJE	The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity
Brief Summary	Clinically, iodinated contrast-medium (CM) is widely used in angiography and computerized tomography. CM-induced nephropathy (CMIN) is one major complication after application of CM. Therefore, how to prevent CMIN is always one of the hot topics concerned by nephrologists, cardiologists, and radiologists. The present study is aimed to determine the norepinephrine concentration, oxidative markers, and tubular damage markers in the urine samples of patients undergoing intravenous pyelography (IVP). The working hypothesis is high-osmolarity contrast media (HOCM) causes more oxidative stress and greater tubular damage than iso-osmolarity contrast media (IOCM).
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Case-Only Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Retention: Samples Without DNA Description: The urine samples are collected just before and 30 minutes after IVP.The samples are immediately frozen at -80'C until analyzed.
Sampling Method	Non-Probability Sample
Study Population	Adult patients (> 18 years old) Undergoing IVP with an appropriate medical indication Signing informed consent
Condition ^ICMJE	Kidney Diseases
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	80
Completion Date	Not Provided
Primary Completion Date	January 2008 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Adult patients (> 18 years old) Undergoing IVP with an appropriate medical indication Signing informed consent Exclusion Criteria: 1. Without signing informed consent
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Taiwan

Administrative Information
NCT Number ^ICMJE	NCT00632892
Other Study ID Numbers ^ICMJE	96013
Has Data Monitoring Committee	Yes
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Far Eastern Memorial Hospital
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Far Eastern Memorial Hospital
Verification Date	February 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top